Moderna: experimental treatment selected by FDA

(CercleFinance.com) - Moderna announced that the US FDA has selected its investigational therapy mRNA-3705 for the START pilot program, which aims to accelerate the development of new treatments for rare diseases.


The selection of mRNA-3705 for the START program will enable Moderna to benefit from improved and accelerated communications with the FDA, facilitating the clinical development of the treatment.

mRNA-3705 is a treatment in development for methylmalonic acidemia (MMA), a rare and potentially fatal metabolic disease caused by a deficiency in the MUT enzyme.

Currently, mRNA-3705 is being evaluated in a phase 1/2 study, known as the Landmark study, to test the safety and tolerability of the treatment in patients aged one year and over.


Copyright (c) 2024 CercleFinance.com. All rights reserved.